Ariceum Therapeutics, a biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, and UCB, a global biopharmaceutical company, entered into an exclusive, strategic research collaboration agreement to identify and develop novel systemic targeted radiopharmaceuticals for the treatment of solid tumors and immune-related diseases. Under the terms of the research collaboration, UCB and Ariceum will utilize each other’s technolog...